|
Aging and Cancer: Can We Do One Without the Other?
Co-Chairpersons: Elizabeth H. Blackburn, University of California, San Francisco, CA; and Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, TX
- Elizabeth H. Blackburn
- Ronald A. DePinho
- Leonard P. Guarente, Massachusetts Institute of Technology, Cambridge, MA
- Cynthia Kenyon, University of California, San Francisco, CA
Antibody Drug Conjugates: Advances in Understanding the Structure-Function Relationship
Co-Chairpersons: Hanspeter Gerber, Pfizer, Pearl River, NY; and Emma M. Lees, Novartis Institutes for BioMedical Research, Emeryville, CA
- Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA
- Paul G. Polakis, Genentech, Inc., South San Francisco, CA
- Puja Sapra, Pfizer, Pearl River, NY
- Peter D. Senter, Seattle Genetics, Inc., Bothell, WA
Bringing Targeted Agents to Cancer Prevention
Co-Chairpersons: Andrea DeCensi, E.O. Ospedali Galliera, Genova, Italy; and Karen T. Liby, Dartmouth Medical School, Hanover, NH
- Andrea DeCensi
- Karen T. Liby
- Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA
- Avrum E. Spira, Boston University School of Medicine, Boston, MA
Comprehensive Tumor Genotyping for Treatment Selection in Clinical Oncology
Chairperson: Marc Ladanyi, Memorial Sloan-Kettering Cancer Center, New York, NY
- Michael F. Berger, Memorial Sloan-Kettering Cancer Center, New York, NY
- Christopher I. Corless, Oregon Health & Science University, Portland, OR
- Anthony John Iafrate, Massachusetts General Hospital, Boston, MA
- Vincent A. Miller, Memorial Sloan-Kettering Cancer Center, New York, NY
Concepts and Challenges in Bringing Next-Generation Sequencing to the Clinic
Co-Chairpersons: John D. Carpten, Translational Genomics Research Institute, Phoenix, AZ; and Stephen B. Gruber, University of Michigan, Ann Arbor, MI
- John D. Carpten
- Stephen B. Gruber
- Giselle L. Sholler, Van Andel Research Institute, Grand Rapids, MI
- Victor E. Velculescu, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
HIV Malignancies: Current Dilemmas and Future Directions
Co-Chairpersons: Richard F. Ambinder, Johns Hopkins University School of Medicine, Baltimore, MD; and Elizabeth Chiao, Baylor College of Medicine, Houston, TX
- Richard F. Ambinder
- Corey Casper, Fred Hutchinson Cancer Research Center, Seattle, WA
- Elizabeth Chiao
- Meredith S. Shiels, National Cancer Institute, Bethesda, MD
Novel Approaches to Cancer Chemoprevention
Co-Chairpersons: Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX; and Zigang Dong, University of Minnesota Hormel Institute, Austin, MN
- Zigang Dong
- Ernest T. Hawk
- Paul J. Limburg, Mayo Clinic College of Medicine, Rochester, MN
- Chinthalapally V. Rao, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Postmenopausal Hormone Therapy, Cancer, and Other Health Outcomes: Where Are We Now?
Co-Chairpersons: Ross L. Prentice, Fred Hutchinson Cancer Research Center, Seattle, WA; and Bette Caan, Kaiser Permanente, Oakland, CA
- Garnet L. Anderson, Fred Hutchinson Cancer Research Center, Seattle, WA
- Rowan T. Chlebowski, David Geffen School of Medicine at UCLA, Torrance, CA
- Graham A. Colditz, Washington University School of Medicine, Saint Louis, MO
- James V. Lacey, Jr., City of Hope, Duarte, CA
Preclinical and Clinical Evaluation of PI3K Pathway Inhibitors
Co-Chairpersons: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA
- José Baselga
- Lewis C. Cantley
- Langdon L. Miller, Calistoga Pharmaceuticals, Seattle, WA
- Ramon E. Parsons, Columbia University, New York, NY
Recent Advances in the Biology and Therapeutic Targeting of the mTOR Pathway
Co-Chairpersons: Robert T. Abraham, Pfizer Pharmaceuticals, Pearl River, NY; and David M. Sabatini, MIT Whitehead Institute for Biomedical Research, Cambridge, MA
- Elizabeth Petri Henske, Brigham and Women's Hospital, Boston, MA
- Leon O. Murphy, Novartis, Cambridge, MA
- David M. Sabatini
- David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY
Targeting the Cell Cycle in Cancer
Co-Chairpersons: Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; and Helen M. Piwnica-Worms, Washington University School of Medicine, St. Louis, MO
- Tak W. Mak, University of Toronto, Toronto, ON, Canada
- Helen M. Piwnica-Worms
- Geoffrey I. Shapiro
- Stephen R. Wedge, AstraZeneca R&D, Macclesfield, United Kingdom
Targeting the EGFR Family with Small Molecules
Co-Chairpersons: William Pao, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Mark A. Lemmon, University of Pennsylvania School of Medicine, Philadelphia, PA
- Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA
- Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
- Mark A. Lemmon
- William Pao
|